MedTrace Logo

Molecular Characterization of CTCs and ctDNA in Blood and Plasma Samples From Patients With Metastatic and/or Hormone-Resistant Prostate Cancer

NCT02370355 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2017-04-17

No results posted yet for this study

Summary

This research trial studies molecular characterization of circulating tumor cells (CTCs) and circulating tumor (ct) deoxyribonucleic acid (DNA) in blood and plasma samples from patients with prostate cancer that has spread to other places in the body and/or has not responded to previous treatment with hormones. Studying samples of blood and plasma collected from patients with prostate cancer before, during, and/or after treatment in the laboratory may help doctors learn more about changes that occur in DNA and identify the development of drug resistance.

Conditions

  • Hormone-Resistant Prostate Cancer
  • Metastatic Prostate Carcinoma

Interventions

OTHER

Cytology Specimen Collection Procedure

Undergo collection of blood samples

OTHER

Laboratory Biomarker Analysis

Correlative studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Southern California

    lead OTHER

Principal Investigators

  • Mitchell Gross · University of Southern California

Eligibility

Min Age
19 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-23
Primary Completion
2016-06-08
Completion
2016-06-08

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02370355 on ClinicalTrials.gov